Feasibility of Ambulatory Talc. Pleurodesis

Launched by DAVID ROLLINS · Nov 8, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to treat patients with a condition called malignant pleural effusion, which is when fluid builds up around the lungs due to cancer. The usual treatment requires a hospital stay of about four days, which can be tough for patients who may not want to be in the hospital for that long. This study aims to see if we can safely provide this treatment on an outpatient basis, allowing patients to go home the same day. The goal is to improve their comfort and quality of life while still effectively managing their symptoms.

To participate in this trial, patients should be between the ages of 65 and 74 and must have a life expectancy of at least 30 days. They should also be able to perform some daily activities with minimal assistance. Patients who have had previous unsuccessful treatments on the same side or have certain lung conditions may not be eligible. Those who join the trial will provide feedback on their experience, helping us understand if this new approach is acceptable and beneficial for them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Malignant pleural effusion
• • Life expectancy \>30 days
• • WHO PS 1-2 (3 if due to dyspnoea)
• Exclusion Criteria:
• • Previous failed pleurodesis (on affected side)
• • Known non-expansile lung